129 related articles for article (PubMed ID: 18818880)
1. Bone marrow transplantation for severe aplastic anemia secondary to temozolomide.
Morris EB; Kasow K; Reiss U; Ellison D; Broniscer A
J Neurooncol; 2009 Jan; 91(2):237-9. PubMed ID: 18818880
[TBL] [Abstract][Full Text] [Related]
2. A rare case of aplastic anemia caused by temozolomide.
George BJ; Eichinger JB; Richard TJ
South Med J; 2009 Sep; 102(9):974-6. PubMed ID: 19668033
[TBL] [Abstract][Full Text] [Related]
3. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.
Jalali R; Singh P; Menon H; Gujral S
J Neurooncol; 2007 Oct; 85(1):105-7. PubMed ID: 17505778
[TBL] [Abstract][Full Text] [Related]
4. Temozolomide induced bone marrow Suppression--A single institution outcome analysis and review of the literature.
Kourelis TV; Buckner JC; Gangat N; Patnaik MM
Am J Hematol; 2015 Sep; 90(9):E183-4. PubMed ID: 26010271
[No Abstract] [Full Text] [Related]
5. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children: results of a multiinstitutional study (SJHG-98).
Broniscer A; Iacono L; Chintagumpala M; Fouladi M; Wallace D; Bowers DC; Stewart C; Krasin MJ; Gajjar A
Cancer; 2005 Jan; 103(1):133-9. PubMed ID: 15565574
[TBL] [Abstract][Full Text] [Related]
6. An analysis of temozolomide-related adverse drug reactions reported to the medicines and healthcare products regulatory agency through the yellow card scheme aiming to characterise idiosyncratic profound bone marrow suppression tantamount to aplastic anaemia.
Dixit S; Hingorani M; Allgar V
Clin Oncol (R Coll Radiol); 2014 Feb; 26(2):120-1. PubMed ID: 24183933
[No Abstract] [Full Text] [Related]
7. Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.
Villano JL; Collins CA; Manasanch EE; Ramaprasad C; van Besien K
Lancet Oncol; 2006 May; 7(5):436-8. PubMed ID: 16648049
[No Abstract] [Full Text] [Related]
8. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Sure D; Dunn I; Norden A; Anderson WS
Clin Neurol Neurosurg; 2010 Oct; 112(8):741-2. PubMed ID: 20434832
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Provenzale JM; McLendon RE; Gururangan S; Bigner DD; Herndon JE; Avgeropoulos N; Finlay J; Tourt-Uhlig S; Affronti ML; Evans B; Stafford-Fox V; Zaknoen S; Friedman HS
J Clin Oncol; 2003 Feb; 21(4):646-51. PubMed ID: 12586801
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
11. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors.
Sterba J; Pavelka Z; Slampa P
Neoplasma; 2002; 49(2):117-20. PubMed ID: 12088104
[TBL] [Abstract][Full Text] [Related]
12. The safety of the temozolomide in patients with malignant glioma.
Dario A; Tomei G
Curr Drug Saf; 2006 May; 1(2):205-22. PubMed ID: 18690931
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Lashford LS; Thiesse P; Jouvet A; Jaspan T; Couanet D; Griffiths PD; Doz F; Ironside J; Robson K; Hobson R; Dugan M; Pearson AD; Vassal G; Frappaz D;
J Clin Oncol; 2002 Dec; 20(24):4684-91. PubMed ID: 12488414
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy followed by adjuvant temozolomide treatment of malignant glioma.
Yang TM; Wang HC; Lin YJ; Lin WC; Lu CH; Chang WN; Chang HW; Ho JT
Surg Neurol; 2008 Dec; 70 Suppl 1():S1:60-3. PubMed ID: 19061770
[TBL] [Abstract][Full Text] [Related]
15. An Australian experience with temozolomide for the treatment of recurrent high grade gliomas.
Harris MT; Rosenthal MA; Ashley DL; Cher L
J Clin Neurosci; 2001 Jul; 8(4):325-7. PubMed ID: 11437571
[TBL] [Abstract][Full Text] [Related]
16. A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas.
Panetta JC; Kirstein MN; Gajjar AJ; Nair G; Fouladi M; Stewart CF
Math Biosci; 2003 Nov; 186(1):29-41. PubMed ID: 14527745
[TBL] [Abstract][Full Text] [Related]
17. Therapy for recurrent high-grade gliomas: does continuous dose-intense temozolomide have a role?
Wen PY
J Clin Oncol; 2010 Apr; 28(12):1977-9. PubMed ID: 20308652
[No Abstract] [Full Text] [Related]
18. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.
Gerber DE; Grossman SA; Zeltzman M; Parisi MA; Kleinberg L
Neuro Oncol; 2007 Jan; 9(1):47-52. PubMed ID: 17108062
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas.
De Vos FY; Gijtenbeek JM; Bleeker-Rovers CP; van Herpen CM
Crit Rev Oncol Hematol; 2013 Mar; 85(3):373-82. PubMed ID: 22925496
[TBL] [Abstract][Full Text] [Related]
20. Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma.
Yaman E; Coskun U; Ozturk B; Buyukberber S; Kaya AO; Coskun O; Buyukberber N; Yildiz R; Benekli M
J Clin Neurosci; 2009 Apr; 16(4):591-2. PubMed ID: 19201195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
